|
1
|
Kong P, Christia P and Frangogiannis NG:
The pathogenesis of cardiac fibrosis. Cell Mol Life Sci.
71:549–574. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dzeshka MS, Lip GY, Snezhitskiy V and
Shantsila E: Cardiac fibrosis in patients with atrial fibrillation:
Mechanisms and clinical implications. J Am Coll Cardiol.
66:943–959. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Segura AM, Frazier OH and Buja LM:
Fibrosis and heart failure. Heart Fail Rev. 19:173–185. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edgley AJ, Krum H and Kelly DJ: Targeting
fibrosis for the treatment of heart failure: A role for
transforming growth factor-β. Cardiovasc Ther. 30:e30–e40. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Espira L and Czubryt MP: Emerging concepts
in cardiac matrix biology. Can J Physiol Pharmacol. 87:996–1008.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fan D, Takawale A, Lee J and Kassiri Z:
Cardiac fibroblasts, fibrosis and extracellular matrix remodeling
in heart disease. Fibrogenesis Tissue Repair. 5:152012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barnes JL and Gorin Y: Myofibroblast
differentiation during fibrosis: Role of NAD(P)H oxidases. Kidney
Int. 79:944–956. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weber KT, Sun Y, Tyagi SC and Cleutjens
JP: Collagen network of the myocardium: Function, structural
remodeling and regulatory mechanisms. J Mol Cell Cardiol.
26:279–292. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Swynghedauw B: Molecular mechanisms of
myocardial remodeling. Physiol Rev. 79:215–262. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nature reviews. Cancer. 6:857–866.
2006.PubMed/NCBI
|
|
11
|
Feng H, Wang Y, Su J, Liang H, Zhang CY,
Chen X and Yao W: MicroRNA-148a suppresses the proliferation and
migration of pancreatic cancer cells by down-regulating ErbB3.
Pancreas. 45:1263–1271. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Jiaqi C, Zhaoying C and Huimin C:
MicroRNA-506-3p regulates neural stem cell proliferation and
differentiation through targeting TCF3. Gene. 593:193–200. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vienberg S, Geiger J, Madsen S and
Dalgaard LT: MicroRNAs in metabolism. Acta Physiol (Oxf).
219:346–361. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thum T, Catalucci D and Bauersachs J:
MicroRNAs: Novel regulators in cardiac development and disease.
Cardiovasc Res. 79:562–570. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van Rooij E, Sutherland LB, Thatcher JE,
DiMaio JM, Naseem RH, Marshall WS, Hill JA and Olson EN:
Dysregulation of microRNAs after myocardial infarction reveals a
role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA.
105:13027–13032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei C, Kim IK, Kumar S, Jayasinghe S, Hong
N, Castoldi G, Catalucci D, Jones WK and Gupta S: NF-κB mediated
miR-26a regulation in cardiac fibrosis. J Cell Physiol.
228:1433–1442. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang X, Tsitsiou E, Herrick SE and
Lindsay MA: MicroRNAs and the regulation of fibrosis. FEBS J.
277:2015–2021. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X, Wang HX, Li YL, Zhang CC, Zhou CY,
Wang L, Xia YL, Du J and Li HH: MicroRNA Let-7i negatively
regulates cardiac inflammation and fibrosis. Hypertension.
66:776–785. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Q, Han L, Yan W, Ji X, Han R, Yang J,
Yuan J and Ni C: miR-489 inhibits silica-induced pulmonary fibrosis
by targeting MyD88 and Smad3 and is negatively regulated by lncRNA
CHRF. Sci Rep. 6:309212016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang K, Liu F, Zhou LY, Long B, Yuan SM,
Wang Y, Liu CY, Sun T, Zhang XJ and Li PF: The long noncoding RNA
CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res.
114:1377–1388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoon S and Eom GH: HDAC and HDAC
inhibitor: From cancer to cardiovascular diseases. Chonnam Med J.
52:1–11. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li M, Zheng Y, Yuan H, Liu Y and Wen X:
Effects of dynamic changes in histone acetylation and deacetylase
activity on pulmonary fibrosis. Int Immunopharmacol. 52:272–280.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li X, Wu XQ, Xu T, Li XF, Yang Y, Li WX,
Huang C, Meng XM and Li J: Role of histone deacetylases(HDACs) in
progression and reversal of liver fibrosis. Toxicol Appl Pharmacol.
306:58–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eom GH, Cho YK, Ko JH, Shin S, Choe N, Kim
Y, Joung H, Kim HS, Nam KI, Kee HJ and Kook H: Casein kinase-2α1
induces hypertrophic response by phosphorylation of histone
deacetylase 2 S394 and its activation in the heart. Circulation.
123:2392–2403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Katwa LC, Guarda E and Weber KT:
Endothelin receptors in cultured adult rat cardiac fibroblasts.
Cardiovascular research. 27:2125–2129. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Y, Wang B, Zhou C and Bi Y: Matrine
induces apoptosis in angiotensin II-stimulated hyperplasia of
cardiac fibroblasts: Effects on Bcl-2/Bax expression and caspase-3
activation. Basic Clin Pharmacol Toxicol. 101:1–8. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zaitone SA and Abo-Gresha NM: Rosuvastatin
promotes angiogenesis and reverses isoproterenol-induced acute
myocardial infarction in rats: Role of iNOS and VEGF. Eur J
Pharmacol. 691:134–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li M, Jiang Y, Jing W, Sun B, Miao C and
Ren L: Quercetin provides greater cardioprotective effect than its
glycoside derivative rutin on isoproterenol-induced cardiac
fibrosis in the rat. Can J Physiol Pharmacol. 91:951–959. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Huang XR, Wei LH, Chung AC, Yu CM
and Lan HY: miR-29b as a therapeutic agent for angiotensin
II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling. Mol
Ther. 22:974–985. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR,
Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N, et al: Inhibition of
histone deacetylation blocks cardiac hypertrophy induced by
angiotensin II infusion and aortic banding. Circulation. 113:51–59.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kong Y, Tannous P, Lu G, Berenji K,
Rothermel BA, Olson EN and Hill JA: Suppression of class I and II
histone deacetylases blunts pressure-overload cardiac hypertrophy.
Circulation. 113:2579–2588. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W,
Wang T, Floss T, Goettlicher M, Noppinger PR, Wurst W, et al: Hdac2
regulates the cardiac hypertrophic response by modulating Gsk3 beta
activity. Nat Med. 13:324–331. 2007. View
Article : Google Scholar : PubMed/NCBI
|
